Professor Chris Rayner: Ledger

Role	Organisation	Sources
	Glyscend	Brandon Capital portfolio, Brandon BioCatalyst portfolio
Gastroenterologist	Royal Adelaide Hospital	Brandon Capital portfolio, Brandon BioCatalyst portfolio
Gastroenterologist, U of Adelaide	Glyscend, Inc.	Brandon BioCatalyst portfolio (Wed 29 Sep 2021), Brandon BioCatalyst portfolio (Tue 3 Aug 2021), Glyscend, Inc. team page
Professor	University of Adelaide	Brandon Capital portfolio, Brandon BioCatalyst portfolio
Professor	Centre of Research Excellence in Translating Nutritional Science to Good Health	Brandon BioCatalyst portfolio (Tue 3 Aug 2021), Brandon Capital portfolio (Tue 3 Aug 2021), Brandon Capital portfolio (Fri 12 Jun 2020), Brandon Capital portfolio (Fri 12 Jun 2020), Brandon BioCatalyst portfolio (Fri 12 Jun 2020)

Series A $29m

Glyscend Therapeutics commences South Australia Phase I clinical trial to progress new type 2 diabetes treatment

Glyscend Therapeutics, a Johns Hopkins spin-out, is starting a Phase I trial of its type 2 diabetes pill in Adelaide; the piece recalls its AUD$29 million Series A led by Brandon Capital's MRCF.

Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio

Unnamed stage $29m

Adelaide Type 2 Diabetes researchers zero in on an ‘operation in a pill’

Adelaide-backed biotech Glyscend is recruiting volunteers for phase 1 trials of a pill mimicking gastric bypass surgery to treat type 2 diabetes, funded with $29 million from Brandon Capital's MRCF, Santé Ventures and Breakout Labs.

Brandon Capital portfolio Tue 3 Aug 2021 Glyscend CMAX Medical Research Commercialisation Fund (MRCF)PayPal Royal Adelaide Hospital University of Adelaide Brandon Capital Breakout Labs Santé Ventures Ashish Nimgaonkar Professor Chris Rayner Peter Thiel

Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio

Unnamed stage $29m

Adelaide Type 2 Diabetes researchers zero in on an 'operation in a pill'

Glyscend Therapeutics, an Adelaide-Baltimore biotech, is recruiting volunteers for phase 1 trials of GLY-200, a pill mimicking gastric bypass for type 2 diabetes, developed with $29 million from MRCF, Santé Ventures and Breakout Labs.

Brandon BioCatalyst portfolio Tue 3 Aug 2021 Glyscend Brandon Capital CMAX PayPal Royal Adelaide Hospital University of Adelaide Breakout Labs Medical Research Commercialisation Fund (MRCF)Santé Ventures Ashish Nimgaonkarand Professor Chris Rayner Peter Thiel

Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio

Unnamed stage $29m

Innovative type two diabetes treatment scores $29m

Glyscend's diabetes pill has raised $29 million with backing from Brandon Capital, Santé Ventures and Breakout Labs, ahead of planned human trials in Adelaide.

Brandon BioCatalyst portfolio Fri 12 Jun 2020 Glyscend Centre of Research Excellence in Translating Nutritional Science to Good Health PayPal Royal Adelaide Hospital Thiel Foundation University of Adelaide Brandon Capital Breakout Labs Santé Ventures Dr Bob Soh Professor Chris Rayner Professor Michael Horowitz Peter Thiel

Also Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio

Professor Chris Rayner

Roles

Coverage

Glyscend Therapeutics commences South Australia Phase I clinical trial to progress new type 2 diabetes treatment

Adelaide Type 2 Diabetes researchers zero in on an ‘operation in a pill’

Adelaide Type 2 Diabetes researchers zero in on an 'operation in a pill'

Innovative type two diabetes treatment scores $29m